anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Percutaneous coronary intervention has revolutionized the management of coronary artery disease, yet in-stent restenosis (ISR) remains a clinical challenge, especially when complicated by calcification. Various techniques are available for the modification of calcified ISR, including super-high-pressure balloon dilation, in-stent rotational atherectomy, excimer laser coronary atherectomy and intravascular lithotripsy (IVL). This case report presents a challenging scenario of very late calcified ISR in a large coronary artery, highlighting diagnostic and interventional considerations. A patient with a history of multiple cardiovascular risk factors presented with infero-lateral ST-elevation myocardial infarction. Coronary angiography revealed severe very late ISR in the distal right coronary artery. Despite initial interventions, severe stent under-expansion persisted due to extensive calcification. The operator employed shockwave lithotripsy alongside a non-compliant balloon to achieve the vessel diameter and an optimal stent expansion. While the evidence for some interventions is limited, case series and registries suggest promising outcomes with IVL, particularly in refractory cases. Our proposed approach addresses the limitations posed by vessel diameter, demonstrating potential efficacy in this challenging case. This case report emphasizes the need for tailored therapeutic strategies and the integration of innovative techniques in managing calcified ISR, with IVL emerging as a promising option in selected cases.
<P>PROBLEM TO BE SOLVED: To provide the improvement in stability of vaccine containing an aluminum salt, especially the improvement in pH stability (buffer) and in adjuvant adsorption at various temperatures and/or the improvement in antigen stability (e.g. lowering of hydrolysis).  <P>SOLUTION: The above improvement is performed by providing a composition containing an antigen, the aluminum salt, and histidine and a process for producing the composition (including a step for mixing the antigen, the aluminum salt, and histidine). Amino acid histidine is used to improve the stability of vaccine containing the aluminum salt, can improve pH stability and adjuvant adsorption, and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt. The antigen in vaccine may be a protein or a saccharide and is preferably from N. meningitidis.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
BACKGROUND: Atraumatic subarachnoid haemorrhage (SAH) is associated with high morbidity and mortality. Proposed mechanisms for red blood cell (RBC) clearance from the subarachnoid space (SAS) are erythrolysis, erythrophagocytosis or through efflux along cerebrospinal fluid (CSF) drainage routes. We aimed to elucidate the mechanisms of RBC clearance from the SAS to identify targetable efflux pathways.
METHODS: Autologous fluorescently-labelled RBCs along with PEGylated 40 kDa near-infrared tracer (P40D800) were infused via the cisterna magna (i.c.m.) in female reporter mice for lymphatics or for resident phagocytes. Drainage pathways for RBCs to extracranial lymphatics were evaluated by in vivo and in situ near-infrared imaging and by immunofluorescent staining on decalcified cranial tissue or dural whole-mounts.
FINDINGS: RBCs drained to the deep cervical lymph nodes 15 min post i.c.m. infusion, showing similar dynamics as P40D800 tracer. Postmortem in situ imaging and histology showed perineural accumulations of RBCs around the optic and olfactory nerves. Numerous RBCs cleared through the lymphatics of the cribriform plate, whilst histology showed no relevant fast RBC clearance through dorsal dural lymphatics or by tissue-resident macrophage-mediated phagocytosis.
INTERPRETATION: This study provides evidence for rapid RBC drainage through the cribriform plate lymphatic vessels, whilst neither fast RBC clearance through dorsal dural lymphatics nor through spinal CSF efflux or phagocytosis was observed. Similar dynamics of P40D800 and RBCs imply open pathways for clearance that do not impose a barrier for RBCs. This finding suggests further evaluation of the cribriform plate lymphatic function and potential pharmacological targeting in models of SAH.
FUNDING: Swiss National Science Foundation (310030_189226), SwissHeart (FF191155).
To investigate the radiomics models for the differentiation of simple and non-simple acute appendicitis. This study retrospectively included 334 appendectomy cases (76 simple and 258 non-simple cases) for acute appendicitis. These cases were divided into training (n = 106) and test cohorts (n = 228). A radiomics model was developed using the radiomic features of the appendix area on CT images as the input variables. A CT model was developed using the clinical and CT features as the input variables. A combined model was developed by combining the radiomics model and clinical information. These models were tested, and their performance was evaluated by receiver operating characteristic curves and decision curve analysis (DCA). The variables independently associated with non-simple appendicitis in the combined model were body temperature, age, percentage of neutrophils and Rad-score. The AUC of the combined model was significantly higher than that of the CT model (P = 0.041). The AUC of the radiomics model was also higher than that of the CT model but did not reach a level of statistical significance (P = 0.053). DCA showed that all three models had a higher net benefit (NB) than the default strategies, and the combined model presented the highest NB. A nomogram of the combined model was developed as the graphical representation of the final model. It is feasible to use the combined information of clinical and CT radiomics models for the differentiation of simple and non-simple acute appendicitis.
The present invention relates to a traditional Chinese medicine composition for treating keloid, which takes more than 10 Chinese herbal medicines of danshen root, raw oyster, pumice stone and common selfheal fruit-spike etc. as the raw materials. The present invention has the effects of promoting blood circulation, removing blood stasis, softening and resolving hard mass. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results and the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for treating keloid. The present invention is characterized by accurate efficacy, safety, reliability, low price, no toxicity and side effects.
No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
Mitochondrial forms account approximately 1-2% of all nonsyndromic cases of hearing loss (HL). One of the most common causative variants of mtDNA is the m.1555A > G variant of the MT-RNR1 gene (OMIM 561000). Currently the detection of the m.1555A > G variant of the MT-RNR1 gene is not included in all research protocols. In this study this variant was screened among 165 patients with HL from the Republic of Buryatia, located in the Baikal Lake region of Russia. In our study, the total contribution of the m.1555A > G variant to the etiology of HL was 12.7% (21/165), while the update global prevalence of this variant is 1.8% (863/47,328). The m.1555A > G variant was notably more prevalent in Buryat (20.2%) than in Russian patients (1.3%). Mitogenome analysis in 14 unrelated Buryat families carrying the m.1555A > G variant revealed a predominant lineage: in 13 families, a cluster affiliated with sub-haplogroup A5b (92.9%) was identified, while one family had the D5a2a1 lineage (7.1%). In a Russian family with the m.1555A > G variant the lineage affiliated with sub-haplogroup F1a1d was found. Considering that more than 90% of Buryat families with the m.1555A > G variant belong to the single maternal lineage cluster we conclude that high prevalence of this variant in patients with HL in the Baikal Lake region can be attributed to a founder effect.
Long COVID is the term used to describe patients who present with persistent symptoms after recovering from SARS-CoV-2 infection. Patients exhibit a range of symptoms and commonly report respiratory and cardiac phenomena including breathlessness, feeling tight chested and having persistent tachycardias. Survey data suggests up to 87% of patients discharged from hospital after COVID-19 infection have ongoing symptoms 60 days after discharge, with 43% describing breathlessness. In the USA, 35% of patients treated for SARS-CoV-2 as an outpatient have ongoing symptoms, with a similar percentage of the population unable to return to their normal work. The natural history and pathophysiology of long COVID is not yet fully understood. Few studies have explored pulmonary function in post-COVID patients. There are suggestions that functional limitation is related to lung abnormalities affecting both ventilation (air flow) and perfusion (blood flow), possibly caused by micro-blood clots. Establishing a relatively cost-effective and accessible way of diagnosing these will allow clinicians to treat or signpost the patients to the correct services. This is vital at both the patient and health system level.

Full pulmonary function testing is routinely done in respiratory clinics to investigate breathlessness and diagnose conditions such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. It includes a measure of transfer factor, an estimate of the efficiency of the diffusion of gas from the lung into the blood stream. The lungs' ability to absorb carbon monoxide (CO) is measured as a proxy for the ability to absorb oxygen. It is hypothesised that long COVID patients with breathlessness have abnormal gas transfer due to lung tissue damage at an alveolar level and/or perfusion abnormalities such as micro clots. Dynamic X-ray is a new, innovative technology to image the thoracic cavity throughout the breathing cycle allowing assessment of pulmonary function and possibly diagnose small ventilation-perfusion abnormities. Liverpool hosts the only dynamic X-ray machine in Europe. Potential applications beyond COVID are numerous, including filling diagnostic gaps in many lung diseases where expensive lung function testing is an unrealistic possibility in the medium term.
In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
Risk Summary

Hydrocodone is present in human milk. A published lactation study reports variable concentrations of hydrocodone and hydromorphone (an active metabolite) in breast milk with administration of hydrocodone to nursing mothers in the early post-partum period. This lactation study did not assess breastfed infants for potential adverse drug reactions. There is potential for sedation and respiratory depression resulting from infant exposure to hydrocodone and its metabolites in breast milk.

Acetaminophen is present in human milk in small quantities after oral administration. Based on data from more than 15 nursing mothers, the calculated infant daily dose of acetaminophen is approximately 1 to 2% of the maternal dose. There is one well-documented report of a rash in a breastfed infant that resolved when the mother stopped acetaminophen use and recurred when she resumed acetaminophen use.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Benzhydrocodone and Acetaminophen tablets and any potential adverse effects on the breastfed child from Benzhydrocodone and Acetaminophen tablets or from the underlying maternal condition.

Clinical Considerations

Infants exposed to Benzhydrocodone and Acetaminophen tablets through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
In two large randomized multicenter trials, remission induction therapy for acute nonlymphocytic leukemia (ANLL) with mitoxantrone 12 mg/m2 daily for 3 days as a 10-minute intravenous infusion and cytarabine 100 mg/m2 for 7 days given as a continuous 24-hour infusion was compared with daunorubicin 45 mg/m2 daily by intravenous infusion for 3 days plus the same dose and schedule of cytarabine used with mitoxantrone. Patients who had an incomplete antileukemic response received a second induction course in which mitoxantrone or daunorubicin was administered for 2 days and cytarabine for 5 days using the same daily dosage schedule. Response rates and median survival information for both the U.S. and international multicenter trials are given in Table 3:

In these studies, two consolidation courses were administered to complete responders on each arm. Consolidation therapy consisted of the same drug and daily dosage used for remission induction, but only 5 days of cytarabine and 2 days of mitoxantrone or daunorubicin were given. The first consolidation course was administered 6 weeks after the start of the final induction course if the patient achieved a complete remission. The second consolidation course was generally administered 4 weeks later. Full hematologic recovery was necessary for patients to receive consolidation therapy. For the U.S. trial, median granulocyte nadirs for patients receiving mitoxantrone + cytarabine for consolidation courses 1 and 2 were 10/mm3 for both courses, and for those patients receiving daunorubicin + cytarabine nadirs were 170/mm3 and 260/mm3, respectively. Median platelet nadirs for patients who received mitoxantrone + cytarabine for consolidation courses 1 and 2 were 17,000/mm3 and 14,000/mm3, respectively, and were 33,000/mm3 and 22,000/mm3 in courses 1 and 2 for those patients who received daunorubicin + cytarabine. The benefit of consolidation therapy in ANLL patients who achieve a complete remission remains controversial. However, in the only well-controlled prospective, randomized multicenter trials with mitoxantrone in ANLL, consolidation therapy was given to all patients who achieved a complete remission. During consolidation in the U.S. study, two myelosuppression-related deaths occurred in the mitoxantrone arm and one on the daunorubicin arm. However, in the international study there were eight deaths on the mitoxantrone arm during consolidation which were related to the myelosuppression and none on the daunorubicin arm where less myelosuppression occurred.
A thread formed from fibres of a linear high polymeric substance, which contains in its molecule an atom or atoms of atomic number not less than 40, is incorporated as a tell-tale material in a surgical dressing, such as a gauze swab or pad.  A surgeon may thus readily determine by X-ray examination whether or not a dressing has been removed after an operation.  The fibre-forming substance is preferably a highly-insoluble alginate of barium or other heavy element and its stability to aqueous liquids may be increased by incorporating a synthetic resin in the fibres.  The insolubility of the fibre-forming substance in water and other liquids may be increased by subjecting it to the action of cross-linking agents. Barium alginate yarn may be obtained by immersing calcium alginate yarn in barium chloride solution until the resultant double decomposition reaches equilibrium, and then transferring the yarn to successive baths of the same solution until substantially all the calcium has been replaced by barium.  Barium alginate yarn may also be obtained by extruding a solution of sodium alginate into barium chloride solution.  The yarn may be rendered visually detectable by dyeing it or by colouring it with a chromium or other metallic salt. The stability of the alginate yarn to aqueous treatments may be increased by treating it with a partly condensed formaldehyde resin, e.g. a urea - formaldehyde resin, which is then hardened. The yarn may be soaked in a detergent solution to remove brittleness, and may then be rinsed and dried.  Yarns of heavy metal cellulose glycolates may be used instead of alginate yarns.ALSO:A surgical dressing such as a gauze swab or pad has incorporated therein, as tell-tale material opaque to X-rays, a thread formed from fibres of a linear high-polymeric substance containing in its molecule an atom or atoms of atomic number not less than 40.  A surgeon may thus readily determine whether or not a dressing has been removed after an operation.  The fibre-forming substance may be a highly-insoluble alginate of barium or other heavy element and its stability to aqueous liquids may be increased by incorporating a synthetic resin, e.g. a urea-formaldehyde resin, in the fibres.  The yarn may be impregnated with a partially condensed synthetic resin which is then hardened, e.g. by baking.  Brittleness produced by the resin treatment may be removed by soaking in a detergent solution. Yarns of heavy metal cellulose glycolates may be used instead of alginate yarns.
Cervical cancer (CC) is a cancer arising from the cervix. Human papillomavirus (HPV) infection causes more than 90% of the cases. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Worldwide, CC is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women. The treatment of CC consists of surgical intervention, radiation, chemotherapy and immunotherapy.

Adoptive immunotherapy with cytotoxic T lymphocytes reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of CC-specific engineered immune effectors including cytotoxic T lymphocytes in patients.
The present invention relates to Chinese medicine for resisting depression and a preparation method for the medicine. The medicine comprises bupleurum root, angelica root, largehead atractylodes rhizome, peony, indian bread, liquorice root, cortex moutan and cape jasmine fruit. The present invention is characterized in that the medicine also comprises scutellaria root, peach seed and safflower, and the medicine comprises the raw materials of the following proportion by weight: 3 to 45 of the bupleurum root, 6 to 50 of the angelica root, 4 to 50 of the largehead atractylodes rhizome, 5 to 60 of the peony, 3 to 80 of the indian bread, 1 to 20 of the liquorice root, 3 to 60 of the cortex moutan, 3 to 60 of the cape jasmine fruit, 4 to 60 of the scutellaria root, 5 to 60 of the peach seed and 2 to 30 of the safflower. After one half quantity of the angelica root, the largehead atractylodes rhizome and the white peony alba and full of the indian bread are taken to be dried and ground, and the mixture is sieved by 100 meshes to obtain fine powder for standby; coarse dregs, one half of the angelica root, the largehead atractylodes rhizome and the white peony alba and other seven kinds of Chinese medicine (the bupleurum root, the scutellaria root, the peach seed, the cape jasmine fruit, the cortex moutan, the sichuan safflower and the liquorice root) are decocted for 2 hours in the first time and for 45 minutes in the second and the third times; the weight ratio of water and medicine is 2.5 to 3.5: 1; the decoction is filtered, and filtrate is combined and concentrate into a thick paste state to be mixed with the fine powder; granules are prepared by drying, grinding and sieving, and are tableted and packed to form the medicine. The scutellaria root which is added on the basis of jiawei xiaoyao san is used for eliminating dampness, dissipating phlegm and clearing heat. The scutellaria root belongs to heart channels of upper warmer, and can balance heat of the heart and.
Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
The study will be conducted in patients with advanced NSCLC (stage IIIB-IV) who have MPE requiring therapeutic drainage, and are also eligible for treatment with chemotherapy plus bevacizumab (as defined in protocol Section 6.0). All patients will undergo placement of a Pleur-XTM catheter as part of routine practice. Eligible patients may enroll in the protocol prior to, or within 10 days following placement of their Pleur-XTM catheter. Upon enrollment, patients will be given a logsheet on which to record the volume of pleural fluid drained from their catheter. Only patients who, in the opinion of the treating physician, do not have a hemorrhagic pleural effusion (grossly bloody, or pleural fluid hemoglobin concentration \> 25% of blood hemoglobin concentration) may remain on study. In addition, only patients who, in the opinion of the treating physician, have satisfactory placement of their Pleur-XTM catheter may remain on study.

Approximately 15 patients will be enrolled with the goal to treat 10 patients with chemotherapy plus bevacizumab. The additional enrollments will be necessary in that it is estimated that approximately 1 in 3 patients will be taken off study due to failure of Pleur-XTM catheter placement, or discovery of hemorrhagic effusion.

Patients who remain on study will begin chemotherapy. All eligible patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent. Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab. Acceptable chemotherapy regimens for this protocol are detailed in Section 5.0 of the protocol. Only the administration of bevacizumab will be governed by the protocol (Section 11.0). Dose reductions of all other drugs will be made according to routine clinical practice. Pleural fluid will be drained from the Pleur-XTM at least every other day (qod), and volume recorded by the patient in a log book. Pleur-XTM catheters may be removed when pleural symphysis is achieved (defined in Section 12.0), or at the discretion of the treating physician. The schedule of follow-up visits may vary according to the chemotherapy regimen, however all patients must be evaluated in the clinic at least every 3 weeks with a doctor visit to record drainage volume, and status of their Pleur-XTM catheter.
This study aims to use urine samples to understand the effect of toxins such as environmental toxins, heavy metals, PFAS and mycotoxins on GI and overall health. Urine samples will be tested using mass-spectroscopy-based techniques. A 'total toxicity score' will be calculated based on the urine analysis of toxins. A 'symptoms score' will be determined using the 'Symptom History' form which will be used to assess the patient's GI conditions. Additionally, a 'diagnosis score' will be calculated from the diagnosis generated in the electronic medical record (EMR). The determined 'total toxicity score' will be correlated with the 'symptoms score' and the 'diagnosis score.' The observations from this study will help us understand the potential effect of environmental toxins, heavy metals, PFAS and mycotoxins on GI and overall health.